Resverlogix Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVXCF research report →
About the company
Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials.
- CEO
- Donald J. McCaffrey
- IPO
- 2009
- Employees
- 19
- HQ
- Calgary, AB, CA
Price Chart
- Market Cap
- $22.19M
- P/E
- -2.38
- P/S
- 0.00
- P/B
- -0.21
- EV/EBITDA
- -27.93
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 6.67%
- ROIC
- 35.53%
- Revenue
- $0 · 0.00%
- Net Income
- $-7,902,965 · -3.51%
- EPS
- $-0.03 · -0.36%
- Op Income
- $-5,203,523
- FCF YoY
- 14.31%
- 52W High
- $0.21
- 52W Low
- $0.03
- 50D MA
- $0.07
- 200D MA
- $0.07
- Beta
- 1.04
- Avg Volume
- 14.24K
Get TickerSpark's AI analysis on RVXCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RVXCF coverage
Recent articles, reports, and earnings notes.
No research on RVXCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RVXCF report →Similar companies
Peers in the same neighborhood.